GENEVA--(BUSINESS WIRE)-- Alcon, the global leader in eye care dedicated to helping people see brilliantly, today proudly announced that more than 175 million of its intraocular lenses (IOLs) have ...

Alcon, the global leader in eye care dedicated to helping people see brilliantly, today proudly announced that more than 175 million of its intraocular lenses (IOLs) have been implanted worldwide.9,+ ...

Earnings call Alcon’s Q4 2025 sales rose 7% YoY to $2.7B, with core EPS of $0.78 and strong innovation-led growth across both Surgical and Vision Care. Management issued 2026 guidance for 5–7% sales ...

PanOptix delivers outstanding patient satisfaction and freedom from glasses; Vivity has a proven exceptionally low rate of ...

The Tecnis PureSee IOL is the first FDA-approved extended depth of focus IOL maintaining contrast sensitivity comparable to ...

The FDA approved the Tecnis PureSee IOL, an extended depth of focus IOL for cataract surgery, according to a press release ...

FDA approval supports US commercialization of TECNIS PureSee, an EDOF IOL for implantation during cataract surgery, with availability anticipated later in 2026. PureSee is positioned to preserve ...

Using sulcus lenses in cases of intraoperative complications.Inspecting and monitoring the lens during implantation to recognize any defects.

Medical Disclaimer: This article is provided for general information and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek advice from a qualified ...